TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Atropine With Orthokeratology in Childhood Myopia Control (AOK) -A Randomized Controlled Trial
Brief Summary: This study aims to compare effects in retardation of myopia progression of combined ortho-k and 0.01% atropine therapy with those of ortho-k alone.Myopia control methods mainly focus on optical and pharmaceutical interventions . Currently, overnight-wear orthokeratology (ortho-k), is used extensively in Hong Kong with approximately 50% retardation effect. Pharmaceutical methods have focused on the use of atropine eye drops to slow myopic progression.The use of 1% atropine was limited by the manifestation of side effects and rebound effect.However, both side effect and rebound effect was minimal with 0.01% atropine.It was suggested that 0.01% was the optimum concentration for controlling myopia.The mechanisms of neither ortho-k nor atropine in myopia control are fully understood.It is believed that ortho-k and atropine act via different mechanisms.It is possible that by combining these two methods, additional retardation of myopia progression could be achieved.


Options:
A: Arm Label: Single-vision glasses; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Orthokeratology with normal compression factor; Type: SHAM_COMPARATOR; Interventions: Device: Orthokeratology | Arm Label: Orthokeratology with increased compression factor; Type: ACTIVE_COMPARATOR; Interventions: Device: Orthokeratology | Intervention Type: DEVICE; Name: Orthokeratology; Assigned to Arm(s): Orthokeratology with increased compression factor, Orthokeratology with normal compression factor
B: Arm Label: intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: increasing time spent outdoors | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: increasing time spent outdoors; Assigned to Arm(s): intervention group
C: Arm Label: Dual Focus Soft Contact Lens; Type: EXPERIMENTAL; Interventions: Device: Dual Focus Soft Contact Lens | Arm Label: Single Vision Soft Contact Lens; Type: PLACEBO_COMPARATOR; Interventions: Device: Single Vision Soft Contact Lens | Intervention Type: DEVICE; Name: Dual Focus Soft Contact Lens; Assigned to Arm(s): Dual Focus Soft Contact Lens | Intervention Type: DEVICE; Name: Single Vision Soft Contact Lens; Assigned to Arm(s): Single Vision Soft Contact Lens
D: Arm Label: ortho-k and 0.01% atropine eye drops; Type: EXPERIMENTAL; Interventions: Drug: 0.01% atropine eye drops, Device: ortho-k | Arm Label: ortho-k; Type: ACTIVE_COMPARATOR; Interventions: Device: ortho-k | Intervention Type: DRUG; Name: 0.01% atropine eye drops; Assigned to Arm(s): ortho-k and 0.01% atropine eye drops | Intervention Type: DEVICE; Name: ortho-k; Assigned to Arm(s): ortho-k, ortho-k and 0.01% atropine eye drops

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cannabinoids for Behavioral Problems in Autism Spectrum Disorder: A Double Blind, Randomized, Placebo-controlled Trial With Crossover.
Brief Summary: This study aims to assess the safety, tolerability and efficacy of cannabinoids mix \[cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio, BOL Pharma, Israel\] for behavioral problems in children and youth with ASD.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vasopressin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vasopressin | Intervention Type: DRUG; Name: Vasopressin; Assigned to Arm(s): Vasopressin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): N/A
C: Arm Label: citalopram hydrobromide; Type: EXPERIMENTAL; Interventions: Drug: citalopram hydrobromide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DRUG; Name: citalopram hydrobromide; Assigned to Arm(s): citalopram hydrobromide | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo
D: Arm Label: Cannabinoids - 99% pure cannabinoids mix; Type: EXPERIMENTAL; Interventions: Drug: Cannabinoids - 99% pure cannabinoids mix | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cannabinoids - whole plant extract; Type: EXPERIMENTAL; Interventions: Drug: Cannabinoids - whole plant extract | Intervention Type: DRUG; Name: Cannabinoids - 99% pure cannabinoids mix; Assigned to Arm(s): Cannabinoids - 99% pure cannabinoids mix | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cannabinoids - whole plant extract; Assigned to Arm(s): Cannabinoids - whole plant extract

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: RAUORA: Cytisine Versus Varenicline for Smoking Cessation
Brief Summary: To evaluate the effectiveness, safety, and cost-effectiveness of cytisine plus behavioural support compared to varenicline plus behavioural support for smoking cessation, in indigenous Māori (or family of Māori) who smoke and are motivated to quit.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: Cytisine plus behavioural support; Type: EXPERIMENTAL; Interventions: Drug: Cytisine, Behavioral: Behavioural support | Arm Label: Varenicline plus behavioural support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioural support, Drug: Varenicline | Intervention Type: DRUG; Name: Cytisine; Assigned to Arm(s): Cytisine plus behavioural support | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Cytisine plus behavioural support, Varenicline plus behavioural support | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline plus behavioural support
C: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
D: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Improve the South African Government's Community Health Workers' Capacities to Deliver Evidence-based Interventions for Optimizing HIV Outcomes and Reducing Its Comorbidities
Brief Summary: The purpose of this study is to address the United States Office of AIDS Research highest priorities: improving the workforce, reducing health disparities, and addressing HIV comorbidities. UCLA will randomize the government-funded community health workers (CHW) from 16 clinics in matched rural areas in the Eastern Cape in South Africa to either: 1) the Accountable Condition (AC) in which additional monitoring and accountability systems that Philani routinely uses are implemented or 2) a Control Condition (CC), of initial Philani training, but ongoing supervision and monitoring consistent with local government practices.


Options:
A: Arm Label: Accountable Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Accountable Condition | Arm Label: Control Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Accountable Condition; Assigned to Arm(s): Accountable Condition- 8 clinics | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Control Condition- 8 clinics
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: ACT Intervention; Type: EXPERIMENTAL; Interventions: Other: ACT | Intervention Type: OTHER; Name: ACT; Assigned to Arm(s): ACT Intervention
C: Arm Label: FSI-R (Intervention group); Type: EXPERIMENTAL; Interventions: Behavioral: Family Strengthening Intervention in Rwanda (FSI-R) | Arm Label: TAU (Treatment as Usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family Strengthening Intervention in Rwanda (FSI-R); Assigned to Arm(s): FSI-R (Intervention group)
D: Arm Label: Maternal support to become mother; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal support to become mother | Arm Label: Control group: usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Group: usual care | Intervention Type: BEHAVIORAL; Name: Maternal support to become mother; Assigned to Arm(s): Maternal support to become mother | Intervention Type: BEHAVIORAL; Name: Control Group: usual care; Assigned to Arm(s): Control group: usual Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Improve the South African Government's Community Health Workers' Capacities to Deliver Evidence-based Interventions for Optimizing HIV Outcomes and Reducing Its Comorbidities
Brief Summary: The purpose of this study is to address the United States Office of AIDS Research highest priorities: improving the workforce, reducing health disparities, and addressing HIV comorbidities. UCLA will randomize the government-funded community health workers (CHW) from 16 clinics in matched rural areas in the Eastern Cape in South Africa to either: 1) the Accountable Condition (AC) in which additional monitoring and accountability systems that Philani routinely uses are implemented or 2) a Control Condition (CC), of initial Philani training, but ongoing supervision and monitoring consistent with local government practices.


Options:
A: Intervention Type: BEHAVIORAL; Name: Home Nurse Visit; Assigned to Arm(s): N/A
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
C: Arm Label: Durham Connects Eligible Group; Type: EXPERIMENTAL; Interventions: Other: Durham Connects | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Durham Connects; Assigned to Arm(s): Durham Connects Eligible Group
D: Arm Label: Accountable Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Accountable Condition | Arm Label: Control Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Accountable Condition; Assigned to Arm(s): Accountable Condition- 8 clinics | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Control Condition- 8 clinics

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Improve the South African Government's Community Health Workers' Capacities to Deliver Evidence-based Interventions for Optimizing HIV Outcomes and Reducing Its Comorbidities
Brief Summary: The purpose of this study is to address the United States Office of AIDS Research highest priorities: improving the workforce, reducing health disparities, and addressing HIV comorbidities. UCLA will randomize the government-funded community health workers (CHW) from 16 clinics in matched rural areas in the Eastern Cape in South Africa to either: 1) the Accountable Condition (AC) in which additional monitoring and accountability systems that Philani routinely uses are implemented or 2) a Control Condition (CC), of initial Philani training, but ongoing supervision and monitoring consistent with local government practices.


Options:
A: Intervention Type: BEHAVIORAL; Name: Home Visiting; Assigned to Arm(s): N/A
B: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral education; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral education intervention | Intervention Type: BEHAVIORAL; Name: Behavioral education intervention; Assigned to Arm(s): Behavioral education
C: Arm Label: Accountable Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Accountable Condition | Arm Label: Control Condition- 8 clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Control Condition | Intervention Type: BEHAVIORAL; Name: Accountable Condition; Assigned to Arm(s): Accountable Condition- 8 clinics | Intervention Type: BEHAVIORAL; Name: Control Condition; Assigned to Arm(s): Control Condition- 8 clinics
D: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral education; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral education intervention | Intervention Type: BEHAVIORAL; Name: Behavioral education intervention; Assigned to Arm(s): Behavioral education

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Low-molecular Heparin Infusion as Anticoagulation for Nocturnal Home Hemodialysis
Brief Summary: There is a lack of data in the literature about the use of low-molecular weight heparin (LMWH) as anticoagulation for nocturnal home hemodialysis (NHHD). This study aims to evaluate the efficacy and safety of LMWH, administered by infusion method, as compared to unfractionated heparin as anticoagulation for NHHD treatment.


Options:
A: Arm Label: EVODIAL dialyzer and Selectbag citrate; Type: EXPERIMENTAL; Interventions: Device: EVODIAL dialyzer and Selectbag citrate | Arm Label: Regional citrate anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Device: Regional citrate anticoagulation | Intervention Type: DEVICE; Name: EVODIAL dialyzer and Selectbag citrate; Assigned to Arm(s): EVODIAL dialyzer and Selectbag citrate | Intervention Type: DEVICE; Name: Regional citrate anticoagulation; Assigned to Arm(s): Regional citrate anticoagulation
B: Arm Label: Vitamin K antagonist; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: rivaroxaban; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban | Arm Label: rivaroxaban and vitamin K2; Type: ACTIVE_COMPARATOR; Interventions: Drug: rivaroxaban, Dietary Supplement: Vitamin K2 | Intervention Type: DRUG; Name: rivaroxaban; Assigned to Arm(s): rivaroxaban, rivaroxaban and vitamin K2 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin K2; Assigned to Arm(s): rivaroxaban and vitamin K2
C: Arm Label: LMWH arm; Type: EXPERIMENTAL; Interventions: Drug: Nadroparin | Arm Label: UFH arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Unfractionated heparin | Intervention Type: DRUG; Name: Nadroparin; Assigned to Arm(s): LMWH arm | Intervention Type: DRUG; Name: Unfractionated heparin; Assigned to Arm(s): UFH arm
D: Arm Label: "EvoCit"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoCit | Arm Label: "EvoHep"; Type: ACTIVE_COMPARATOR; Interventions: Device: EvoHep | Intervention Type: DEVICE; Name: EvoCit; Assigned to Arm(s): "EvoCit" | Intervention Type: DEVICE; Name: EvoHep; Assigned to Arm(s): "EvoHep"

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy
Brief Summary: Patients living with multiple myeloma (MM) have an increased risk of venous thromboembolism (VTE) due to the disease itself and the use of targeted therapies, including immunomodulatory drugs (IMiDs). Prevention of VTE has become a major management challenge during MM treatment. There is a paucity of data with respect to the non-vitamin K oral anticoagulants (NOACs) in the cancer population. However, the NOACs offer comparable efficacy but improved safety compared with warfarin. Apixaban has shown excellent safety and efficacy for treatment and prevention of recurrent VTE (1,2). The safety and efficacy of apixaban for primary prevention of VTE in MM patients has not been established.

Aim #1: To quantify the 6-month rate of major and clinically relevant non-major bleeding in MM patients receiving IMiDs who are prescribed apixaban 2.5 mg orally twice daily for primary prevention of VTE.

Hypothesis #1: The 6-month rate of major and clinically relevant non-major bleeding in MM patients receiving IMiDs who are prescribed apixaban 2.5 mg orally twice daily for primary prevention of VTE will be ≤3% (2). Although the MM population, in general, has a higher medical acuity than that of the previous large randomized controlled trials of apixaban, we will be selecting a stable population of MM patients who are appropriate for immunomodulatory therapy.

Aim #2: To quantify 6-month rate of symptomatic VTE in MM patients receiving IMiDs who are prescribed apixaban 2.5 mg orally twice daily for primary prevention of VTE.

Hypothesis #2: The 6-month rate of symptomatic VTE in MM patients receiving IMiDs who are prescribed apixaban 2.5 mg orally twice daily for primary prevention of VTE will be \<7% (3). Although additional therapies for MM such as dexamethasone and erythropoietin-stimulating agents may further increase the risk of VTE, the rate of incident VTE should be reduced to \<7% with apixaban.


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban
B: Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: gemcitabine hydrochloride; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: diagnostic laboratory biomarker analysis; Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: dalteparin | Intervention Type: DRUG; Name: dalteparin; Assigned to Arm(s): A, B, C
D: Arm Label: Rivaroxaban; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): Rivaroxaban | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study With NIVOlumab or Continuation of Therapy as an Early SWITCH Approach in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) and Disease Control After 3 Months of Treatment With a Tyrosine Kinase Inhibitor
Brief Summary: This study aims to assess the survival benefit from an early switch approach from sunitinib or pazopanib (10-12 weeks of 1st-line therapy) to nivolumab (anti-angiogenic to immunotherapy switch).


Options:
A: Arm Label: Nivolumab (A); Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: TKI (B); Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib, Drug: Pazopanib | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab (A) | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): TKI (B) | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): TKI (B)
B: Arm Label: Lenvatinib; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib | Arm Label: Lenvatinib plus Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Lenvatinib, Drug: Everolimus | Arm Label: Everolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Everolimus | Intervention Type: DRUG; Name: Lenvatinib; Assigned to Arm(s): Lenvatinib, Lenvatinib plus Everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus, Lenvatinib plus Everolimus
C: Arm Label: Axitinib; Type: EXPERIMENTAL; Interventions: Drug: Axitinib (AG-013736) | Arm Label: Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Axitinib (AG-013736); Assigned to Arm(s): Axitinib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib
D: Arm Label: Dovitinib + best supportive care (BSC); Type: EXPERIMENTAL; Interventions: Drug: Dovitinib | Arm Label: Sorafenib + BSC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Dovitinib; Assigned to Arm(s): Dovitinib + best supportive care (BSC) | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Sorafenib + BSC

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
Brief Summary: This study aims to evaluate safety and efficacy of dimethyl fumarate treatment in patients with primary progressive multiple sclerosis (PPMS).

Half of the patients will receive dimethyl fumarate and the other half will receive placebo.


Options:
A: Intervention Type: DRUG; Name: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody); Assigned to Arm(s): N/A
B: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM
C: Arm Label: Active drug; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl fumarate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dimethyl fumarate; Assigned to Arm(s): Active drug | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)

Answer: C